Case Study: Novartis Pharma’s global licensing deal to develop & commercialise MOR106
MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys... Read More
Benitec’s Axovant exclusive rights to gene therapy for OPMD
Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the... Read More
Deal Insight: Daiichi Sankyo, DarwinHealth R&D agreement
Daiichi Sankyo Company, Limited and DarwinHealth announced they have entered into a research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s... Read More
Insight on XOMA Corp and Novartis Licensing Deal
Novartis has bought the rights to Xoma’s gevokizumab. Novartis AG bagged global commercial license for Xoma Corp.’s anti-IL-1 beta monoclonal antibody gevokizumab... Read More
Samsung Bioepis and Takeda’s Co-development deal for novel biologics
Korean biosimilars manufacturer Samsung Bioepis Co Ltd. will team up with Japanese drugmaker Takeda Pharmaceutical Company to jointly develop new biologic therapies.... Read More
Insignt on Takeda and Biological E. Ltd (BE) licensing agreements for vaccines
Takeda Pharmaceutical Company (Takeda) and Biological E. Ltd (BE) have entered into a collaboration whereby two licensing agreements to expedite the development... Read More
Merck Licenses Anti-Tau Alzheimer’s Antibody from Teijin Pharma
Posted on29 May 2017
Comments0
Teijin Pharma granted Merck exclusive global rights to develop, manufacture, and commercialize a preclinical-stage anti-tau antibody. Merck says the antibody candidate will... Read More
Otsuka and Teva Sign Licensing Agreement for Japan for Fremanezumab
Posted on15 May 2017
Comments0
Otsuka Pharmaceutical Co., Ltd and Teva Pharmaceutical Industries, Ltd. announce an agreement covering Japan for Otsuka to develop and commercialize Teva’s investigational drug candidate fremanezumab... Read More
Licensing Deal Analysis: Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics
Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics for use in combination with Immunomic’s investigational LAMP-Vax technology Underlying technology is currently in... Read More
AMAG Pharma’s licensing deal with Palatin Technologies for North American rights to Rekynda
Posted on07 Feb 2017
Comments0
AMAG Pharmaceuticals has announced licensing agreement with Palatin Technologies, for exclusive North American commercial rights to Rekynda (bremelanotide), an investigational product developed... Read More